Literature DB >> 17117022

Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi.

Rony Zachariah1, Margaret Fitzgerald, Moses Massaquoi, Olesu Pasulani, Line Arnould, Simon Makombe, Anthony D Harries.   

Abstract

OBJECTIVES: Among adults started on antiretroviral treatment (ART) in a rural district hospital (a) to determine the cumulative proportion of deaths that occur within 3 and 6 months of starting ART, and (b) to identify risk factors that may be associated with such mortality. DESIGN AND
SETTING: A cross-sectional analytical study set in Thyolo district, Malawi.
METHODS: Over a 2-year period (April 2003 to April 2005) mortality within the first 3 and 6 months of starting ART was determined and risk factors were examined.
RESULTS: A total of 1507 individuals (517 men and 990 women), whose median age was 35 years were included in the study. There were a total of 190 (12.6%) deaths on ART of which 116 (61%) occurred within the first 3 months (very early mortality) and 150 (79%) during the first 6 months of initiating ART. Significant risk factors associated with such mortality included WHO stage IV disease, a baseline CD4 cell count under 50 cells/mul and increasing grades of malnutrition. A linear trend in mortality was observed with increasing grades of malnutrition (chi for trend = 96.1, P </= 0.001) and decreasing CD4 cell counts (chi for trend = 72.4, P </= 0.001). Individuals who were severely malnourished [body mass index (BMI) < 16.0 kg/m] had a six times higher risk of dying in the first 3 months than those with a normal nutritional status.
CONCLUSIONS: Among individuals starting ART, the BMI and clinical staging could be important screening tools for use to identify and target individuals who, despite ART, are still at a high risk of early death.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17117022     DOI: 10.1097/QAD.0b013e32801086b0

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  142 in total

1.  Effect of HIV infection on body composition and fat distribution in Rwandan women.

Authors:  Eugene Mutimura; Kathryn Anastos; Mardge Cohen; Agnes Binagwaho; Donald P Kotler
Journal:  J Int Assoc Physicians AIDS Care (Chic)       Date:  2010 May-Jun

2.  Body mass index and risk of tuberculosis and death.

Authors:  Colleen F Hanrahan; Jonathan E Golub; Lerato Mohapi; Nkeko Tshabangu; Tebogo Modisenyane; Richard E Chaisson; Glenda E Gray; James A McIntyre; Neil A Martinson
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

3.  Prevalent tuberculosis and mortality among HAART initiators.

Authors:  Daniel Westreich; Matthew P Fox; Annelies Van Rie; Mhairi Maskew
Journal:  AIDS       Date:  2012-03-27       Impact factor: 4.177

4.  Impact of the immune reconstitution inflammatory syndrome (IRIS) on mortality and morbidity in HIV-infected patients in Mexico.

Authors:  Irma Hoyo-Ulloa; Pablo F Belaunzarán-Zamudio; Brenda Crabtree-Ramirez; Arturo Galindo-Fraga; María Eugenia Pérez-Aguinaga; Juan G Sierra-Madero
Journal:  Int J Infect Dis       Date:  2011-04-13       Impact factor: 3.623

5.  Change over time of mortality predictors after HAART initiation in a Senegalese cohort.

Authors:  Pierre De Beaudrap; Jean-François Etard; René Ecochard; Assane Diouf; Allé Baba Dieng; Vannina Cilote; Ibrahima Ndiaye; Ndèye Fatou Ngom Guèye; Pape Mandoumbé Guèye; Papa Salif Sow; Souleymane Mboup; Ibra Ndoye; Eric Delaporte
Journal:  Eur J Epidemiol       Date:  2008-01-16       Impact factor: 8.082

6.  Predictors for mortality and loss to follow-up among children receiving anti-retroviral therapy in Lilongwe, Malawi.

Authors:  Bradley C Fetzer; Mina C Hosseinipour; Portia Kamthuzi; Lisa Hyde; Brian Bramson; Kebba Jobarteh; Kristine Torjesen; William C Miller; Irving Hoffman; Peter Kazembe; Charles Mwansambo
Journal:  Trop Med Int Health       Date:  2009-06-28       Impact factor: 2.622

7.  Implementation and operational research: Integrated pre-antiretroviral therapy screening and treatment for tuberculosis and cryptococcal antigenemia.

Authors:  Lincoln Pac; Mara Murray Horwitz; Anne Marion Namutebi; Brandon J Auerbach; Aggrey Semeere; Teddy Namulema; Miriam Schwarz; Robert Bbosa; Allan Muruta; David B Meya; Yukari C Manabe
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

8.  Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia.

Authors:  Benjamin H Chi; Albert Mwango; Mark Giganti; Lloyd B Mulenga; Bushimbwa Tambatamba-Chapula; Stewart E Reid; Carolyn Bolton-Moore; Namwinga Chintu; Priscilla L Mulenga; Elizabeth M Stringer; Robert Sheneberger; Peter Mwaba; Jeffrey S A Stringer
Journal:  J Acquir Immune Defic Syndr       Date:  2010-05-01       Impact factor: 3.731

9.  Anthropometric and immunological success of antiretroviral therapy and prediction of virological success in west African adults.

Authors:  Eugène Messou; Delphine Gabillard; Raoul Moh; André Inwoley; Souleymane Sorho; Serge Eholié; François Rouet; Catherine Seyler; Christine Danel; Xavier Anglaret
Journal:  Bull World Health Organ       Date:  2008-06       Impact factor: 9.408

10.  Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia.

Authors:  Benjamin H Chi; Ronald A Cantrell; Isaac Zulu; Lloyd B Mulenga; Jens W Levy; Bushimbwa C Tambatamba; Stewart Reid; Albert Mwango; Alwyn Mwinga; Marc Bulterys; Michael S Saag; Jeffrey S A Stringer
Journal:  Int J Epidemiol       Date:  2009-02-17       Impact factor: 7.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.